Table 3.
Summary and comparison of seroconversion of neutralising antibodies (immunogenicity population)
| ZyCoV-D (n=50) | Placebo (n=47) | p value | |
|---|---|---|---|
| Day 84 | |||
| No | 6 (12·00%) | 27 (57·45%) | .. |
| Yes | 44 (88·00%) | 20 (42·55%) | <0·0001 |
| Day 56 | |||
| No | 12 (24·00%) | 25 (53·19%) | .. |
| Yes | 38 (76·00%) | 22 (46·81)% | 0·0031 |
Data are n (%). GMT=geometric mean titre. GMFR=geometric mean fold rise. Day-wise comparison of proportion of participants, with seroconversion rate based on IgG antibodies as compared with baseline, between ZyCov-D and placebo is evaluated using χ2 test. Significant p value (<0·05) indicates that there is a significant difference between ZyCov-D and placebo based on proportion of participants with seroconversion rate.